Expect a Limited Role for Zurzuvae for Postpartum Depression

February 2024

New Rx zuranolone (Zurzuvae) will be the first ORAL med approved for treatment of postpartum depression.

Think of it as similar to IV brexanolone (Zulresso).

Both mimic the hormone allopregnanolone, which interacts with GABA receptors. This hormone abruptly dips around childbirth...possibly leading to major depression.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote